

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Cancelled).
2. (Currently amended) A composition, comprising a peptide having MTLP ~~selected from the group consisting of an amino acid sequence substantially as set forth in SEQ ID NOS: 3-24~~ SEQ ID NO: 24 and a fragment, motif, derivative, analog or peptidomimetic thereof.
3. (Cancelled).
4. (Currently amended) The composition of claim 2, further comprising an active agent, wherein said peptide ~~the MTLP~~ is complexed to said ~~the~~ active agent.
5. (Cancelled).
6. (Currently amended) The composition of claim 2, further comprising an active particle, wherein said peptide ~~the MTLP~~ is complexed to said ~~the~~ active particle.
7. (Withdrawn) A method for enhancing movement of an active agent across a lipid membrane, comprising a complex selected from the group consisting of a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances movement of the active agent across the lipid membrane.
8. (Withdrawn) A method for enhancing movement of an active particle across a lipid membrane, comprising a MTLP-active particle complex, wherein the MTLP enhances movement of the active particle across the lipid membrane.

9. (Withdrawn) A method for identifying a derivative of a MTLP having enhanced ability to transport an active agent across a lipid membrane, wherein the derivative of the MTLP competes for transport of fMLP across a membrane selected from the group consisting of a cell membrane, an intracellular membrane, the apical and basal membranes of an epithelial cell layer.
10. (Withdrawn) The membrane of claim 9, wherein the epithelial cell layer is a polarized epithelial cell layer.
11. (Withdrawn) A method for treating a pathological disorder in an animal, comprising orally administering to the animal in need of such treatment a complex selected from the group consisting of a MTLP-active agent complex and a MTLP-active particle complex, wherein an amount of the active agent effective to treat the pathological disorder is moved across the gastrointestinal epithelium of the animal into the circulation.
12. (New) A composition according to Claim 4, wherein the active agent is a viral DNA particle.
13. (New) A composition according to Claim 12, wherein the DNA is in the form of a MTLP coated liposome.
14. (New) A pharmaceutical composition comprising a peptide according to Claim 2 and a pharmaceutical carrier.
15. (New) A pharmaceutical composition according to Claim 14, adapted for oral administration.
16. (New) A method of diagnosis of a pathological disorder by oral administration, the method comprising administering an effective amount of the composition according to Claim 2, wherein the active agent is a diagnostic agent.

17. (New) A method of identifying the ability a substance to transport an agent across a lipid membrane, the method comprising applying the agent in the absence or presence of the substance and measuring the degree of inhibition.
18. (New) A method according to Claim 17, wherein the agent is the reporter molecule, fMLP.
19. (New) A composition for use in membrane translocation, the composition consisting of an MTLP comprising an amino acid sequence of SEQ ID NO: 24.
20. (New) A composition of Claim 19, wherein said MTLP is complexed to a liposome.
21. (New) A pharmaceutical composition comprising a composition according to Claim 19 and a pharmaceutical carrier.
22. (New) A pharmaceutical composition according to Claim 20, adapted for oral administration.
23. (New) A composition for use in membrane translocation, the composition comprising an membrane translocating peptide (MTLP) comprising an amino acid sequence of SEQ ID NO: 24, wherein said MTLP comprises D-isomers of amino acids or is a retroinverted peptide.
24. (New) A composition according to Claim 23, wherein said MTLP is complexed to an active agent to be translocated.
25. (New) A composition according to Claim 23, wherein said MTLP is complexed to an active particle to be translocated.
26. (New) A composition to Claim 24, wherein said active agent is a viral DNA particle.

27. (New) A composition according to Claim 26, wherein said DNA is in the form of a MTLIP coated liposome.
28. (New) A pharmaceutical composition comprising a composition according to Claim 23 and a pharmaceutical carrier.
29. (New) A pharmaceutical composition according to Claim 28, adapted for oral administration.
30. (New) A method of diagnosis of a pathological disorder by oral administration, the method comprising administering an effective amount of the composition according to Claim 23, wherein said active agent is a diagnostic agent.